Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis

Kauntz,Henriette; Bousserouel,Souad; Gosse,Francine; Marescaux,Jacques; Raul,Francis

doi:10.3892/ijo.2012.1526

Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis

Authors:
- Henriette Kauntz
- Souad Bousserouel
- Francine Gosse
- Jacques Marescaux
- Francis Raul
View Affiliations

Affiliations: Laboratory of Nutritional Cancer Prevention, EA 4438, Faculty of Medicine, IRCAD, University of Strasbourg, Strasbourg, France, IRCAD - EITS, Strasbourg, France
Published online on: June 25, 2012 https://doi.org/10.3892/ijo.2012.1526
Pages: 849-854
Copyright: © Kauntz et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The flavonolignan silibinin, the major biologically active compound of the milk thistle (Silybum marianum), has been shown to possess anticancer properties in a variety of epithelial cancers. The present study investigated the potential of silibinin as a chemopreventive agent in colon carcinogenesis. The rat azoxymethane (AOM)-induced colon carcinogenesis model was used because of its molecular and clinical similarities to sporadic human colorectal cancer. One week after AOM injection (post-initiation), Wistar rats received daily intragastric feeding of 300 mg silibinin/kg body weight per day until their sacrifice after 7 weeks of treatment. Silibinin-treated rats exhibited a 2-fold reduction in the number of AOM-induced hyperproliferative crypts and aberrant crypt foci in the colon compared to AOM-injected control rats receiving the vehicle. Silibinin-induced apoptosis in the colon mucosal cells was demonstrated by flow cytometry after propodium iodide staining and by colorimetric measurement of caspase-3 activity. Mechanisms involved in silibinin-induced apoptosis included the downregulation of the anti-apoptotic protein Bcl-2 and upregulation of the pro-apoptotic protein Bax, inverting the Bcl-2/Bax ratio to <1. This modulation already takes place at the mRNA expression level as shown by real-time RT-PCR. Furthermore, silibinin treatment significantly (P<0.01) decreased the genetic expression of biomarkers of the inflammatory response such as IL1β, TNFα and their downstream target MMP7, all of them shown to be upregulated during colon carcinogenesis. The downregulation of MMP7 protein was confirmed by western blot analysis. The present findings show the ability of silibinin to shift the disturbed balance between cell renewal and cell death in colon carcinogenesis in rats previously injected with the carcinogen AOM. Silibinin administered via intragastric feeding exhibited potent pro-apoptotic, anti-inflammatory and multi-targeted effects at the molecular level. The effective reduction of preneoplastic lesions by silibinin supports its use as a natural agent for colon cancer chemoprevention.

View Figures

View References

1	Boursi B and Arber N: Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des. 13:2274–2282. 2007. View Article : Google Scholar : PubMed/NCBI
2	Reddy BS: Studies with azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen. 44:26–35. 2004. View Article : Google Scholar : PubMed/NCBI
3	Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon cancer chemoprevention in rats, mice and humans. Eur J Cancer. 41:1911–1922. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hoensch HP and Kirch W: Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. Int J Gastrointest Cancer. 35:187–195. 2005. View Article : Google Scholar : PubMed/NCBI
5	Terpstra OT, Van Blankenstein M, Dees J and Eilers GA: Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology. 92:704–708. 1987.PubMed/NCBI
6	Risio M, Lipkin M, Candelaresi G, Bertone A, Coverlizza S and Rossini FP: Correlations between rectal mucosa cell proliferation and the clinical and pathological features of nonfamilial neoplasia of the large intestine. Cancer Res. 151:1917–1921. 1999.PubMed/NCBI
7	Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis. 15:1049–1054. 1994. View Article : Google Scholar
8	Bird RP and Good K: The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett. 112–113:395–402. 2000.
9	Gazàk R, Walterovà D and Kren V: Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem. 14:315–338. 2007.PubMed/NCBI
10	Singh RP and Agarwal R: Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 41:1969–1979. 2005. View Article : Google Scholar : PubMed/NCBI
11	Singh RP and Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog. 45:436–442. 2006. View Article : Google Scholar : PubMed/NCBI
12	Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM and Agarwal R: Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila). 2:74–83. 2009. View Article : Google Scholar : PubMed/NCBI
13	Velmurugan B, Singh RP, Tyagi A and Agarwal R: Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher rats. Cancer Prev Res (Phila). 1:376–385. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP and Agarwal R: Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia. 12:415–424. 2010.PubMed/NCBI
15	Ravichandran K, Velmurugan B, Gu M, Singh RP and Agarwal R: Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res. 16:4595–4606. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kauntz H, Bousserouel S, Gossé F and Raul F: Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis. 16:1042–1053. 2011. View Article : Google Scholar
17	Bousserouel S, Kauntz H, Gossé F, Bouhadjar M, Soler L, Marescaux J and Raul F: Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol. 36:1485–1490. 2010.PubMed/NCBI
18	Charnley G and Tannenbaum SR: Flow cytometric analysis of the effect of sodium chloride on gastric cancer risk in the rat. Cancer Res. 45:5608–5616. 1985.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
20	Sier CF, Hawinkels LJ, Zijlmans HJ, Zuidwijk K, de Jonge-Muller ES, Ferreira V, Hanemaaijer R, Mulder-Stapel AA, Kenter GG, Verspaget HW and Gorter A: Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol. 27:267–271. 2008.PubMed/NCBI
21	Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
22	Gunter MJ: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 15:1126–1131. 2006. View Article : Google Scholar : PubMed/NCBI
23	Buck I, Morceau F, Grigorakaki C, Dicato M and Diederich M: Linking anemia to inflammation and cancer: the crucial role of TNFα. Biochem Pharmacol. 77:1572–1579. 2009.PubMed/NCBI
24	Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 1:1458–1461. 2006. View Article : Google Scholar : PubMed/NCBI
25	Corpet DE and Tache S: Most effective colon cancer chemopreventive agents in rats: a review of aberrant crypt foci and tumour data, ranked by potency. Nutr Cancer. 43:1–21. 2002. View Article : Google Scholar : PubMed/NCBI
26	Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis. 15:1049–1054. 1994. View Article : Google Scholar
27	Pretlow TP, O’Riordan MA, Pretlow TG and Stellato TA: Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J Cell Biochem. (Suppl)16:G55–G62. 1992. View Article : Google Scholar : PubMed/NCBI
28	Takayama T, Katsuki S, Takahashi Y, et al: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
29	Leeman MF, Curran S and Murray GI: New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 201:528–534. 2003. View Article : Google Scholar : PubMed/NCBI
30	Lu Q, Jiang B, Lin C and Shan T: Dark aberrant crypt foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat. J Exp Clin Cancer Res. 27:262008. View Article : Google Scholar : PubMed/NCBI
31	Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG and Wang TC: Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 14:408–419. 2008. View Article : Google Scholar : PubMed/NCBI
32	Anti M, Armuzzia A, Morinid S, Iasconea E, Pignataroa G, Cocob C, Lorenzettie R, Paoluccia M, Covinoa M, Gasbarrinia A, et al: Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut. 48:238–246. 2001. View Article : Google Scholar : PubMed/NCBI
33	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
34	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
35	Singh RP, Tyagi AK, Zhao J and Agarwal R: Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis. 23:499–510. 2002. View Article : Google Scholar : PubMed/NCBI
36	Bousserouel S, Gossé F, Bouhadjar M, Soler L, Marescaux J and Raul F: Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 23:511–517. 2010.
37	Bousserouel S, Lamy V, Gossé F, Lobstein A, Marescaux J and Raul F: Early modulation of gene expression used as biomarker for chemoprevention in a preclinical model of colon carcinogenesis. Path Int. 61:80–87. 2011. View Article : Google Scholar : PubMed/NCBI